Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).
Kang Y, LoRusso P, Salgia R, Yen C, Lin C, Ramanathan R, Kaminker P, Sokolova I, Bhathena A, Wang L, Naumovski L, Strickler J. Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC). Journal Of Clinical Oncology 2015, 33: 167-167. DOI: 10.1200/jco.2015.33.3_suppl.167.Peer-Reviewed Original ResearchAnti-c-Met antibodySingle-agent activityMET amplificationProgressive diseasePartial responseSubstantial single-agent activityGood responsePrimary untreated tumorsRECIST version 1.1Treatment-refractory tumorsDose-escalation phaseHuman xenograft tumorsC-Met overexpressionPrimary tumor tissuesTumor biopsy tissueLonger PFSAdvanced gastricAdverse eventsPrior linesSystemic therapyRecurrent tumorsPatient populationEsophageal cancerPrimary tumorEscalation phase
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply